Trastuzumab emtansine (T‑DM1; brand example: Kadcyla) doesn’t generally face “sudden generic collapse” the moment a single patent expires, but patent expiry can still put downward pressure on prices through a few common mechanisms:
1) Generic/biosimilar entry (when patents truly expire)
- If the relevant patents covering the product (active ingredient + formulations + manufacturing + specific methods) have expired and there’s no effective exclusivity barrier, biosimilars or competitors can enter.
- For biologics/antibody-drug conjugates, new competition usually takes the form of biosimilars (or sometimes alternative products) rather than classic small‑molecule generics.
- Effect: competition tends to reduce wholesale acquisition cost and net prices (after rebates/discounts), though the size of the drop varies.
2) “Evergreening” delays price drops
Even when an initial patent ends, companies often have additional “layers” of protection (different patents for:
- dosing/regimens,
- specific antibody-drug linker technology,
- manufacturing processes,
- combination uses or new indications).
- Effect: price pressure may be slower or more limited until the full set of exclusivities has run out.
3) Market exclusivity and indication-specific protection
Price outcomes depend on what you mean by “patent expiry”:
- Some countries grant regulatory exclusivity (e.g., for biologic approvals) that can extend protection beyond the first patent.
- New indications can also extend pricing power for that use.
- Effect: even after part of the patent estate expires, prices for certain patients/indications might stay higher longer.
4) Payer behavior and contracting before actual competition
Even before a biosimilar launches, payers may anticipate upcoming entry:
- They may push for rebates, preferred formulary placement, or step therapy adjustments.
- Effect: you can see gradual price movement rather than an abrupt change.
5) Access and procurement dynamics
If the manufacturer anticipates competition, it may:
- lower list prices,
- increase discounting/rebates,
- offer value-based contracts.
- Effect: net price to payers can decline earlier than list price suggests.
What this means in practice
Patent expiry for trastuzumab emtansine typically leads to more competitive pricing over time, but the timeline and magnitude depend on:
- whether a true biosimilar/competitor can launch,
- how strong the remaining patent/exclusivity barriers are,
- and how urgently payers seek substitution.
If you tell me which country (US/EU/UK/etc.) and the specific patent/expiry date or product name you’re referring to, I can give a more concrete explanation of what would be expected for pricing there and when.